Comparative Pharmacology
Head-to-head clinical analysis: A POXIDE versus CENTRAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A POXIDE versus CENTRAX.
A-POXIDE vs CENTRAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABA-A receptor positive allosteric modulator; increases chloride ion influx and neuronal hyperpolarization.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
GERD: 20 mg orally once daily for 4-8 weeks. Erosive esophagitis: 40 mg once daily for 8 weeks. H. pylori eradication: 20 mg twice daily with amoxicillin and clarithromycin for 14 days.
10-30 mg orally, 3-4 times daily.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours (mean 15 hours) in adults with normal renal function. Prolonged to 24-36 hours in elderly or moderate renal impairment (CrCl < 50 mL/min).
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Renal excretion accounts for 60-70% of elimination, predominantly as unchanged drug. Biliary/fecal excretion accounts for 20-30%, with approximately 10% eliminated in feces as metabolites.
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Category C
Category C
Benzodiazepine
Benzodiazepine